论文部分内容阅读
将标记放射性同位素~(125)I 的超液态碘化油(~(125)I-LUF)及自身体毛颗粒混入抗癌药,经导管超选择灌人供瘤动脉,治疗20例肝癌。在这种导向治疗前后分别作 CT、B 超、DSA 及 AFP 等对照检测及~(125)I 放射性测定。结果证明~(125)I 能牢固标记于 LUF,与体毛一起在100μm 直径以下的供瘤末梢动脉中长期滞留,不通过毛细血管进入全身循环,并能将抗瘤药限制在肿瘤局部发挥近距离长时间内照射化疗栓塞作用,对癌外正常组织损伤最小,术后副作用较轻,未发生排异反应,临床疗效满意。
The super-liquid iodized oil (125) I-LUF labeled radioactive isotopic 125I and its body hair particles were mixed into anti-cancer drugs, and the tumor artery was superselectively perfused through a catheter to treat 20 cases of liver cancer. CT, B-ultrasound, DSA, and AFP control tests and ~(125)I radioactivity measurements were performed before and after this targeted treatment. The results demonstrate that ~(125)I can be firmly labeled with LUF and stays in the peripheral arteries of tumors below 100 μm in diameter with body hair, and does not enter the systemic circulation through capillaries, and can limit the use of anti-neoplastic drugs to local tumors. Long-term exposure to chemoembolization had the least damage to normal tissue outside the cancer, and the postoperative side effects were mild. No rejection was observed and the clinical effect was satisfactory.